Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Joanne L C Tan, MBBS, Eric Wong, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Radha Ramanan, MBBS, Andrew B M Lim, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5662.

https://doi.org/10.1182/blood-2019-122363

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients

Ivan S Moiseev, MD PhD, Sergey N. Bondarenko, PhDMD, Elena I Darskaya, MD PhD, Aleksandr Alyanski, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, MD, Sergey Lapin, MD PhD, Elena Surkova, PhD, Varvara Nikolaevna Ovechkina, Olga Vladislavovna Pirogova, MD PhD, Valentina Vladimirovna Porunova, MD, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 5746.

https://doi.org/10.1182/blood-2019-125570

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

Akanksha Chichra, DNB, Lingaraj Nayak, MDDM MDcal Oncology, Rushabh Kothari, MD DM MDcal Oncology, Siddhesh Arun Kalantri, MD, Avinash Bonda, MD DM, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Sadhana Kannan, MSc, Libin J Mathew, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 4493.

https://doi.org/10.1182/blood-2019-128099

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Apoorva Anandan, MD, Pingfu Fu, Merle Kolk, Nicole Ferrari, Arash Rashidi, MD, Melissa Copley, PharmD, James Driscoll, MD PhD, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 5646.

https://doi.org/10.1182/blood-2019-122057

Published: 2019

Journal Articles

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roni Shouval, Adi Eshel, MSc, Ivetta Danylesko, Bar Dubovski, Joshua A Fein, MD, Shalev Fried, Mika Geva, MD, Elizaveta Kouniavsky, Amir A Kuperman, MD MSc, Yoram Louzoun, PhD, Omry Koren, PhD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3265.

https://doi.org/10.1182/blood-2019-125433

Published: 2019

Journal Articles

Clinical Efficacy of Prebiotics on Transplant-Related Complications

Kota Yoshifuji, MD, Kyoko Inamoto, MD, Kazuhiko Kakihana, MD PhD, Megumi Akiyama, MD, Takashi Toya, MD PhD, Aiko Igarashi, MD, Yuho Najima, MD, Noriko Doki, MD PhD, Takeshi Kobayashi, MD, Yuuko Kiridooshi, Kozue Takeshita, MD PhD, Wataru Suda, Atsushi Shiota, Masahira Hattori, MD PhD, Kenya Honda, MD PhD, Hisashi Sakamaki, MD PhD, Kazuteru Ohashi, MD PhD

Blood (2018) 132 (Supplement 1): 4573.

https://doi.org/10.1182/blood-2018-99-114845

Published: 2018

Journal Articles

Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety

Reyad Dada, MD, Azhar Nawaz, Clinical Pharmacy Specialist, Ehab Mosaad Abdelghany, MD, Tarek Boubakra

Blood (2018) 132 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2018-99-111538

Published: 2018

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Michael R. Kurman, MD, Courtney D. DiNardo, MD MSc, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Kiran Naqvi, MD MPH, Farhad Ravandi, MD, Elias J. Jabbour, MD, Ricardo Delumpa, BSN, Timothy Madden, PhD, Gary Maier, PhD, Hiroyuki Iwamura, PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 1438.

https://doi.org/10.1182/blood-2018-99-116613

Published: 2018

Journal Articles

Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

Tatsuya Suwabe, MD, Kyoko Fuse, MD, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD PhD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2018) 132 (Supplement 1): 5712.

https://doi.org/10.1182/blood-2018-99-115844

Published: 2018

Journal Articles

Pegaspargase with Concurrent Radiotherapy in a Once-Every-Three-Weeks Schedule in Patients with Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: A Phase II Study

Hua Wang, MD, Wei Luo, Yue Lu

Blood (2018) 132 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2018-99-113265

Published: 2018

Journal Articles

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Andrei R Shustov, MD, Michi M Shinohara, MD, Shaker R. Dakhil, MD, Gajanan Bhat, Jasmine M. Zain, MD

Blood (2018) 132 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2018-99-119684

Published: 2018

Journal Articles

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Laura Brook Hogan, MD, Teena Bhatla, MD, Sue Rheingold, MD, Lingyun Ji, PhD, Xinxin Xu, Elizabeth A. Raetz, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Patrick Brown, MD

Blood (2018) 132 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2018-99-112269

Published: 2018

Journal Articles

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Megan Sturdy, MD, Rebecca Ye, BA, Trevor L Jenkins, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Leland Metheny, MD, Rachel Zebrowski, RN, Nicole Ferrari, Merle Kolk, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2018-99-113828

Published: 2018

Journal Articles

Addition of Melphalan to Fludarabine/Busulfan (FLU/BU4/MEL) Provides Survival Benefit for Patients with Myeloid Malignancy Following Allogeneic Bone Marrow Transplantation/Peripheral Blood Stem Cell Transplantation

Tomoaki Ueda, Tetsuo Maeda, MD, Kentaro Fukushima, MD PhD, Jiro Fujita, MD PhD, Shinsuke Kusakabe, MD, Takafumi Yokota, MD PhD, Hirohiko Shibayama, MD PhD, Yoshiaki Tomiyama, MD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2099.

https://doi.org/10.1182/blood-2018-99-112328

Published: 2018

NARROW

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Fludarabine Melphalan Versus Fludarabine Treosulfan As Reduced Intensity Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplant - a Retrospective Analysis

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Serum Electrolyte Dynamics in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Oral Mucositis Is Associated with Distinctive Patterns of Oral Microbiota Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Efficacy of Prebiotics on Transplant-Related Complications

Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS)

Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

Pegaspargase with Concurrent Radiotherapy in a Once-Every-Three-Weeks Schedule in Patients with Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: A Phase II Study

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Addition of Melphalan to Fludarabine/Busulfan (FLU/BU4/MEL) Provides Survival Benefit for Patients with Myeloid Malignancy Following Allogeneic Bone Marrow Transplantation/Peripheral Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only